other material
confidence high
sentiment positive
materiality 0.70
Perspective Therapeutics reports Phase 1/2a data for [212Pb]VMT01; no dose-limiting toxicities observed
Perspective Therapeutics, Inc.
- No dose-limiting toxicities; TEAEs mostly Grades 1–2; no renal toxicities reported despite high renal dosimetry.
- At 3.0 mCi dose: 1 RECIST objective response, 2 patients with stable disease at 9 and 11 months.
- At 5.0 mCi dose: patients progressed after first or second cycle; findings consistent with preclinical immunostimulatory effect at lower doses.
- SMC recommends testing 1.5 mCi dose as monotherapy and in combination with nivolumab; combination cohort now enrolling.
- Median 5 prior lines of therapy; FDA Fast Track Designation; plan to update on VMT-α-NET study by year-end.